Therapeutic Advances in Psychopharmacology

Papers
(The median citation count of Therapeutic Advances in Psychopharmacology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Analysis of the clinical characteristics of olanzapine-induced acute pancreatitis55
Olanzapine long-acting injection, discontinuation rates and reasons for discontinuation: 10 years’ experience at a UK high-secure hospital32
Prevalence and predictors of inappropriate prescribing in outpatients with severe mental illness32
Relationship between resilience and mental health among COVID-19 bereaved people: the mediating role of dual process coping32
Disrupted emotion regulation and spontaneous neural activity in panic disorder: a resting-state fMRI study29
History repeating: guidelines to address common problems in psychedelic science29
Comment on: History repeating: guidelines to address common problems in psychedelic science29
The missing link? Pharmacists’ perspectives on discontinuation of long-term antidepressants: a qualitative study28
The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trial23
Incidence of hyperthyroidism in patients with bipolar or schizoaffective disorder with or without lithium: 21-year follow-up from the LiSIE retrospective cohort study21
Who is prescribed valproate and how carefully is this treatment reviewed in UK mental health services? Data from a clinical audit20
Corrigendum to “Managing medical and psychiatric multimorbidity in older patients”19
The efficacy of antipsychotics in the treatment of physical aggressive behavior in patients with dementia in nursing homes17
Brugada syndrome: should we be screening patients before prescribing psychotropic medication?16
Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry16
Reasons for discontinuing and restarting lithium multiple times: a case-register study based on the South London and Maudsley NHS Foundation Trust Clinical Record Interactive Search system16
Risperidone-induced priapism: a case report and literature review15
Monoclonal antibody precision therapy targeting inflammation for bipolar disorder: a narrative review15
Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey13
Antipsychotics and structural brain changes: could treatment adherence explain the discrepant findings?12
Plain Language Summary of Publication: A comparison of once-monthly and once-every-2-months injectable formulations of aripiprazole in people with schizophrenia12
Estimation of cardiac QTc intervals in people prescribed antipsychotics: a comparison of correction factors11
Clinical outcomes following switching antipsychotic treatment due to market withdrawal: a retrospective naturalistic cohort study of pipotiazine palmitate injection (Piportil Depot) discontinuation, s11
Reasons for admission to a general medical hospital for patients taking clozapine11
Exploring the clinical factors affecting lithium dose and plasma level and the effect of brand10
Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review10
Will psilocybin lose its magic in the clinical setting?9
Hypercoagulable state in patients with schizophrenia: different effects of acute and chronic antipsychotic medications9
Corrigendum to ‘Comment on: History repeating: guidelines to address common problems in psychedelic science’8
Risperidone-induced neuroleptic malignant syndrome: a case report8
Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia8
Duration of prior psychotic illness and clozapine response: a retrospective observational study using electronic health records7
Anticholinergic action is rarely a good thing7
Preliminary data from a 4-year mirror-image and multicentre study of patients initiating paliperidone palmitate 6-monthly long-acting injectable antipsychotic: the Paliperidone 2 per Year study6
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series6
High-dose olanzapine in treatment-resistant schizophrenia: a systematic review6
Clozapine blood level assessment using a point-of-care device: feasibility and reliability6
Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depression6
Incorporation of a specialist mental health clinical pharmacist within a primary care network: patient referrals, prescribing decisions, and clinical outcomes6
Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies6
The role of flumazenil in generalised anxiety disorder: a pilot naturalistic open-label study with a focus on treatment resistance6
Decreased citalopram concentration caused by enzyme induction effect of rifampin: a case report6
Increased amisulpride serum concentration in a patient treated with concomitant pregabalin and trazodone: a case report5
The cardiovascular safety of tricyclic antidepressants in overdose and in clinical use5
Drug safety in older patients with alcohol use disorder: a retrospective cohort study5
Management of dyslipidaemia in individuals with severe mental illness: a population-based study in the Greater Copenhagen Area5
Tardive dyskinesia: understanding current challenges in diagnosis and treatment5
Risperidone ISM®: review and update of its usefulness in all phases of schizophrenia5
The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics4
Time to rehospitalization in involuntarily hospitalized individuals suffering from schizophrenia discharged on long-acting injectable antipsychotics or oral antipsychotics4
Olanzapine for the treatment of ICU delirium: a systematic review and meta-analysis4
Managing medical and psychiatric multimorbidity in older patients4
Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan4
Psychosocial interventions to improve adherence in depressed and anxious older adults prescribed antidepressant pharmacotherapy: a scoping review4
Altered orbitofrontal and pars opercularis cortical thickness in betel quid dependence chewers4
Classic psychedelics, health behavior, and physical health4
Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised?4
The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence4
The place of long-acting injectable antipsychotics in the treatment of schizophrenia4
Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery3
Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis3
Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review3
Drug utilization in geriatric psychiatric patients in the emergency department—a cohort study under real-world conditions3
Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study3
Implementing gradual, hyperbolic tapering of long-acting injectable antipsychotics by prolonging the inter-dose interval: an in silico modelling study3
The past, present and future of anticholinergic drugs3
Antipsychotic polypharmacy and clozapine prescribing patterns: evolution and correlates before and after a psychiatric hospitalisation3
0.062689065933228